Table 2.
Dicer alteration trend | Performed assay | Drug resistance | Cancer | Experimental condition | References |
---|---|---|---|---|---|
↑ | Western blot; Quantitative reverse transcriptase PCR | Gefitinib | Lung cancer | Cell culture and human biopsy | [125] |
↓ | Western blot; Quantitative reverse transcriptase PCR | Cisplatin | Ovarian cancer | Cell culture | [126] |
↓ | Immunohistochemical analysis | 5-Fluorouracil | Oral squamous carcinoma | Human biopsy | [127] |
↓ | Western blot | Doxorubicin | Breast cancer | Cell culture | [128] |
↓ | Immunoblot analysis; Quantitative reverse transcriptase PCR | Tamoxifen | Breast cancer | Cell culture | [129] |
↓ | siRNA silencing | Cisplatin | Breast cancer | Cell culture | [130] |
↓ | siRNA silencing | Temozolomide | Glioblastoma | Cell culture | [131] |
↓ | Western blot | Cisplatin | Cervical cancer | Cell culture | [132] |
↑* | Gel mobility-shift assay | Amphiphilic peptide LK-L1C/K6W/L8C | Cervical and breast cancer | Recombinant human Dicer | [133] |
Functional analysis of Dicer activity.